Lifeboat Foundation

That conclusion is based on a study that reviewed genetic testing results from 1.45 million individuals and found that nearly 25 percent of “variants of uncertain significance” were subsequently reclassified — sometimes as less likely to be associated with cancer, sometimes as more likely.

The study appears in the Journal of the American Medical Association (JAMA).

When variations from the norm are discovered in a gene, the variants are classified as “benign,” “likely benign,” “variant of uncertain significance,” “likely pathogenic,” or “pathogenic.”

Today, we have an interview with Dr. Michael Bonkowski, an expert on NAD+ biology and aging from the David Sinclair Lab, Harvard Medical School.

Michael Bonkowski aims to advance our understanding of the links between metabolism, aging, and age-associated diseases. He has published 35 peer-reviewed journal articles and has conducted multiple successful longevity studies. In Dr. David Sinclair’s lab, his research efforts are focused on the role of nutrient sensors’ regulation of endocrine signaling and aging in the mouse. He is also working on direct and indirect ways to drive the activity of these nutrient sensors by using dietary manipulations, small molecules, and chemical treatments.

Michael is trained as a pharmacologist, physiologist, and animal scientist. Some of his areas of expertise include animal physiology, genetics, glucose, and insulin homeostasis, metabolism, assay development, protein biochemistry, and transmission electron microscopy imaging.

Over 500 new gene regions that influence people’s blood pressure have been discovered in the largest global genetic study of blood pressure to date, led by Queen Mary University of London and Imperial College London.

Involving more than one million participants, the results more than triple the number of blood pressure gene regions to over 1,000 and means that almost a third of the estimated heritability for blood pressure is now explained.

The study, published in Nature Genetics and supported by the National Institute for Health Research (NIHR), Medical Research Council and British Heart Foundation, also reports a strong role of these genes, not only in blood vessels, but also within the adrenal glands above the kidney, and in body fat.

Continue reading “Study of one million people leads to world’s biggest advance in blood pressure genetics” »

Given the speed at which reproductive technology has advanced over the past few decades, it doesn’t feel all that far-fetched: A future in which anyone can have a baby, regardless of creed or need, whenever they feel like it. Already, in our present moment, one can buy or sell eggs and sperm; we can give embryos genetic tests to ensure the children they produce don’t have any life-threatening hereditary conditions; and babies can even be born, now, with the genetic information from three parents.

So it follows that we should soon be able to to have pregnancy outside the body — artificial wombs. R ight?

Continue reading “Glimpse: On the Promise of a Future with Artificial Wombs, and Why It’s Being Stopped by the Present” »

http://www.blogtalkradio.com/unlimited-realities-with-lisa-z…lth-future

If you are able to get to Leiden there is an event in support of Lifespan.io on September 29, 12:00 AM – 2:00 PM CEST.

Ending aging and getting rid of its associated conditions is one of humanity’s most ancient dreams. Some of our earliest myths are about heroes going on a quest to find a way to make the whole of mankind forever young. With the current progress in aging research, this is not a dream anymore. In laboratories around the globe, researchers are conducting experiments that show that aging is amenable to medical intervention; we can slow it down and even reverse some age-related changes. As recent experiments on mice demonstrate, there are various ways to postpone aging. Among the most promising treatments are the elimination of harmful senescent cells, drugs that enhance metabolism, genetic and cellular therapies, and calorie restriction. These treatments extend the healthy period of life, and, as a welcome side effect, lifespan in mice by over 25–30%. Some of these methods are currently in human clinical trials and are expected to reach the market 5–10 years from now.

The world’s largest genetic study of hypertension finds that the number of genetic loci involved is three times larger than previously thought.